R
Roland E. Schmieder
Researcher at University of Erlangen-Nuremberg
Publications - 780
Citations - 85811
Roland E. Schmieder is an academic researcher from University of Erlangen-Nuremberg. The author has contributed to research in topics: Blood pressure & Essential hypertension. The author has an hindex of 97, co-authored 717 publications receiving 78138 citations. Previous affiliations of Roland E. Schmieder include Complutense University of Madrid & University of Regensburg.
Papers
More filters
Journal ArticleDOI
Blood pressure and retinal small arteries.
TL;DR: Vascular remodeling, characterized by an increased WLR, of small resistance and large arteries, has been identified as one of the early processes that occurs in response to increased blood pressure (BP) and reflects early hypertensive end-organ damage.
Journal ArticleDOI
CRT-600.06 Cost-Effectiveness of Catheter-Based Radiofrequency Renal Denervation for the Treatment of Uncontrolled Hypertension: An Analysis for the UK Based on Recent Clinical Evidence
Andrew S.P. Sharp,Khoa N. Cao,Mel Lobo,Roland E. Schmieder,Murray D. Esler,David E. Kandzari,Jan B. Pietzsch +6 more
Journal ArticleDOI
Association of Noise Annoyance with Measured Renal Hemodynamic Changes.
Dennis Kannenkeril,Susanne Jung,Christian Ott,Kristina Striepe,Julie Kolwelter,Roland E. Schmieder,Agnes Bosch +6 more
TL;DR: In this paper, the authors demonstrate that noise annoyance-induced stress is associated with changes in renal hemodynamic parameters, such as lower renal plasma flow, higher renal vascular resistance, and higher filtration fraction.
Journal ArticleDOI
Regression of Left Ventricular Hypertrophy-Reply
TL;DR: It seems impossible to separate the effect of antihypertensive agents per se from the effects of the intensive nonpharmacological intervention plus drug therapy, since interactions between the 2 therapeutic strategies most likely occurred.
Journal ArticleDOI
Alcohol-mediated renal denervation in patients with hypertension in the absence of antihypertensive medications.
Atul Pathak,U Rudolph,Manish Saxena,Thomas Zeller,Jochen Müller-Ehmsen,Erik Lipsic,Roland E. Schmieder,Horst Sievert,Marcel Halbach,Faisal Sharif,Helen Parise,Tim A. Fischell,David E. Kandzari,Felix Mahfoud +13 more
TL;DR: The target BP OFF-MED trial as mentioned in this paper investigated the efficacy and safety of alcohol-mediated renal denervation (RDN) in the absence of antihypertensive medications, and the primary efficacy endpoint was the change in mean 24-hour systolic BP at 8 weeks.